View Older Stories View More Recent Stories

Dec 12, 2025 05:13PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.
Dec 12, 2025 05:12PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Dec 12, 2025 05:10PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Dec 12, 2025 05:09PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Dec 11, 2025 05:14PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P.
Dec 11, 2025 05:01PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Dec 11, 2025 05:00AM DISCO Pharmaceuticals Appoints Mark Manfredi as CEO and Announces Final Close of €36 Million Seed Financing
Dec 10, 2025 06:40PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Opportunity Fund I, L.P.
Dec 10, 2025 06:31PM Form 144 Kymera Therapeutics, Filed by: Atlas Venture Fund X, L.P.
Dec 5, 2025 08:00AM K36 Therapeutics announces presentation of First-in-Human Clinical Data for Gintemetostat (KTX-1001) Demonstrating Target Engagement and Clinical Activity in Multiple Myeloma at ASH 2025 and the Appoi
Dec 3, 2025 08:00AM TRIANA Biomedicines Announces Oversubscribed $120M Series B Financing to Advance its Molecular Glue Degrader Pipeline
Nov 18, 2025 12:00PM Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
Nov 17, 2025 08:00AM Imbria Pharmaceuticals Announces Extension of Series B Financing to Advance Ninerafaxstat for Cardiovascular Diseases
Nov 13, 2025 04:23PM Form SCHEDULE 13G/A Dyne Therapeutics, Inc. Filed by: Atlas Venture Fund XI, L.P.
Nov 13, 2025 04:16PM Form 13F-HR Atlas Venture Life Scien For: Sep 30
Nov 3, 2025 03:00AM AAVantgarde Closes $141 Million Series B Financing to Advance its Clinical Programs in Stargardt Disease and Usher 1B Syndrome
Oct 30, 2025 12:16PM Form 13F-NT Atlas Venture Fund VIII, For: Sep 30
Oct 30, 2025 12:14PM Form 13F-NT Atlas Venture Associates For: Sep 30
Oct 30, 2025 12:13PM Form 13F-NT Atlas Venture Associates For: Sep 30
Oct 30, 2025 12:11PM Form 13F-HR Atlas Venture Advisors, For: Sep 30
Oct 27, 2025 07:43AM Lifordi Immunotherapeutics Presents Nonclinical Data on Glucocorticoid Antibody Drug Conjugate LFD-200 at ACR 2025 and Initiates Phase 1 Study in Rheumatoid Arthritis
Oct 21, 2025 04:22PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Opportunity Fund II, L.P.
Oct 21, 2025 04:21PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Fund XI, L.P.
Oct 20, 2025 09:41PM Form SCHEDULE 13D/A Sionna Therapeutics, Filed by: Atlas Venture Fund XI, L.P.
Oct 20, 2025 06:50PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Opportunity Fund II, L.P.
Oct 20, 2025 06:50PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Fund XI, L.P.
Oct 17, 2025 05:27PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.
Oct 17, 2025 05:23PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Oct 17, 2025 04:43PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Oct 17, 2025 04:27PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Fund XI, L.P.
Oct 17, 2025 04:27PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Opportunity Fund II, L.P.
Oct 16, 2025 05:01PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Opportunity Fund II, L.P.
Oct 16, 2025 05:01PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Fund XI, L.P.
Oct 16, 2025 04:47PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Oct 16, 2025 04:46PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Oct 15, 2025 05:00PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Oct 15, 2025 05:00PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.
Oct 14, 2025 04:23PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Fund XI, L.P.
Oct 14, 2025 04:22PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Opportunity Fund II, L.P.
Oct 14, 2025 06:30AM Kailera Therapeutics Announces $600 Million Series B Financing to Further Advance Pipeline of Next-Generation Therapies for the Treatment of Obesity
Oct 10, 2025 04:25PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Opportunity Fund II, L.P.
Oct 10, 2025 04:24PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Fund XI, L.P.
Oct 8, 2025 04:55PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Oct 7, 2025 05:17PM Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.
Oct 7, 2025 07:45AM Affinia Therapeutics Announces Series C Financing to Advance New Class of Gene Therapies Intended to Provide Improved Safety and Efficacy
Oct 6, 2025 04:52PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Opportunity Fund II, L.P.
Oct 6, 2025 04:51PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Fund XI, L.P.
Oct 3, 2025 04:44PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Fund XI, L.P.
Oct 3, 2025 04:44PM Form 144 Sionna Therapeutics, Filed by: Atlas Venture Opportunity Fund II, L.P.
Oct 2, 2025 04:05PM Dyne Therapeutics adds Brian Posner to board of directors
View More Recent Stories View Older Stories